Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Drug Profile

Influenza virus vaccine live intranasal (quadrivalent) - MedImmune

Alternative Names: Fluenz Tetra; FluMist Quadrivalent; Influenza vaccine live-intranasal - MedImmune; MEDI-3250; MEDI-8662; Q-LAIV Flu Vac; Q-LAIV Flu Vaccination; Q/LAIV; Quadrivalent live attenuated influenza vaccine - MedImmune; Quadrivalent live attenuated seasonal influenza vaccine - MedImmune; VN-0107

Latest Information Update: 04 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; Japan Vaccine; MedImmune
  • Class Influenza virus vaccines-live
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 01 Apr 2018 Registered for Influenza virus infections (Prevention, In children, In adolescents, In adults) in Hong Kong (Intranasal)
  • 21 Feb 2018 The Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) votes in favour of a renewed recommendation for the use of influenza virus intranasal vaccine for 2018-2019 season in USA
  • 21 Feb 2018 Immunogenicity data from a phase IV trial in Influenza virus infections released by AstraZeneca
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top